MAIA Biotechnology (MAIA) Earnings Date & Reports

Key Takeaways

• MAIA Biotechnology is scheduled to report results for the third quarter ended September 30, 2026, in early November, with Wall Street modeling a net loss of roughly $0.13 per share.
• As a clinical-stage drug developer with no approved products, MAIA is expected to report little or no revenue, making operating expenses and cash burn the central focus of the quarter.
• Research and development (R&D) spending has climbed sharply as the company advances its lead candidate, ateganosine (THIO), across a Phase 2 and a pivotal Phase 3 trial in non-small cell lung cancer.
• MAIA's cash position was strengthened by a roughly $33 million public offering in March 2026, but investors will be watching how quickly that runway is being consumed.
• For more context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• You can also discover automated trading ideas and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

MAIA Biotechnology, a Chicago-based clinical-stage biopharmaceutical company, is developing targeted immunotherapies for cancer, with its lead candidate ateganosine (THIO) in trials for telomerase-positive non-small cell lung cancer (NSCLC). Because the company has no approved products, it generates no meaningful revenue, so quarterly earnings revolve almost entirely around how much cash it is spending to advance its pipeline. The upcoming third-quarter report offers investors a timely window into R&D momentum, general and administrative (G&A) costs, and whether recent capital raises are sufficient to fund near-term clinical milestones. Given the stock's history of sharp post-earnings moves, the report carries outsized weight for a micro-cap name.

Earnings Expectations

Analysts expect MAIA to post a net loss of approximately $0.13 per share for the third quarter of 2026, a meaningful improvement from the $0.27 loss reported in the same period a year earlier. Revenue is forecast at $0, consistent with the company's pre-commercial, clinical-stage status. The company's own guidance and commentary on cash runway and trial timelines will be closely scrutinized.

Historical results highlight how volatile these prints can be. In the second quarter of 2026, MAIA reported a loss of $0.13 per share, missing the $0.11 consensus estimate. By contrast, the first quarter of 2026 delivered a $0.14 loss that beat the $0.18 consensus, and the fourth quarter of 2025 came in at a $0.08 loss versus a $0.13 estimate. With a single analyst covering the stock, estimate revisions can also swing the comparison meaningfully.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters that include industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking clinical-stage biotech names like MAIA, the AI Screener can help identify comparable setups and momentum signals across the broader healthcare sector.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report remains cautious. MAIA has posted a negative post-earnings drift in recent quarters, and shares have traded well below their 52-week high while holding above their 52-week low, reflecting investor uncertainty about the company's ability to fund its pipeline without further dilution. The market's focus is likely to be less on the headline loss per share and more on qualitative signals: progress on the Phase 3 THIO-104 trial, the pace of enrollment in the Phase 2 THIO-101 study, and any commentary on the company's digital asset treasury strategy, which remains on hold. A larger-than-expected loss or an indication of a near-term financing need could pressure the stock, while clear clinical progress or a disciplined cost narrative could provide support.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter print, the most important variable is MAIA's cash runway. The company ended the second quarter with roughly $27.6 million in cash, supplemented by the approximately $33 million raised through public offerings in March 2026. Investors will want to see whether management reaffirms that this balance is sufficient to reach key clinical milestones, including the interim overall survival analysis for the Phase 3 THIO-104 trial expected in 2027.

Clinical execution will remain the primary value driver. Any updates on THIO-104 enrollment, data readouts, or regulatory interactions are likely to matter more to the stock than the quarterly loss itself. At the same time, cost discipline bears watching: R&D expenses rose roughly 81% year over year in the second quarter as trials expanded, and continued growth could accelerate cash consumption.

Finally, funding strategy remains a key risk. As a pre-revenue biotech, MAIA will likely need additional capital to fully develop and potentially commercialize ateganosine. The timing and structure of any future equity raise will be closely monitored, given its potential dilution impact on shareholders. Investors should track clinical updates, cash balances, and financing announcements over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations